Skip to main content
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 2014 Oct 7;186(14):1090. doi: 10.1503/cmaj.131590

Dry eye disease

Rahul A Sharma 1,, Rookaya Mather 1
PMCID: PMC4188654  PMID: 24821862

Dry eye disease may substantially affect quality of life

Dry eye disease refers to a group of disorders that involve reduced tear production or excessive tear evaporation.1 Dry eye affects up to 30% of people older than 50 years of age.2 Studies evaluating the effect of moderate and severe dry eye on quality of life have shown utility scores similar to those for patients with moderate to severe angina or those receiving dialysis.3

The diagnosis of dry eye is based on clinical presentation

Patients with mild dry eye disease may have conjunctival injection, as well as irritation, itching, soreness, burning or intermittent blurred vision. Visual deterioration may occur in severe cases secondary to ocular surface desiccation or keratinization, or may be a result of corneal scarring, thinning or ulceration.1 Provided that other causes of red eye (e.g., conjunctivitis, blepharitis, contact lens–related keratitis) can be excluded, therapy can be initiated based on signs and symptoms alone.4,5

Artificial tears are first-line therapy for mild dry eye disease

Symptomatic improvement with the use of artificial tears four times per day (first-line therapy) should occur within days, but it may take up to three to four weeks for some patients.1 When appropriate, environmental strategies (e.g., frequent blinking, avoidance of air currents, use of a humidifier) may be helpful. The patient’s medication use should be reviewed because medications that may exacerbate dry eye (e.g., diuretics, selective serotonin receptor inhibitors, tricyclic antidepressants, β-blockers) may need adjustment. Antihistamine medications and local agents that promote vasoconstriction should be avoided.1

Excessive use of preserved artificial tears can exacerbate the symptoms of dry eye

The preservatives in many ophthalmic medications can worsen ocular surface inflammation.5 For patients who require artificial tears more than four to six times per day, preservative-free artificial tears must be used.5

Patients at risk of vision loss require prompt referral to an ophthalmologist

Referral to an ophthalmologist should occur in cases of severe pain or visual loss.1,4 Visual acuity should be assessed before referral. Referral is also recommended for patients whose symptoms do not respond to first-line therapy and those with a history of trauma, chemical injury, Bell palsy, autoimmune disease, (e.g., Sjögren syndrome) or other ocular surface conditions (e.g., herpes simplex, herpes zoster ophthalmicus).3,4 Ophthalmologists may use topical cyclosporine, scleral contact lenses, punctal occlusion or tarsorrhaphy to treat severe cases of dry eye.5

Resources for physicians.

CMAJ invites submissions to “Five things to know about …” Submit manuscripts online at http://mc.manuscriptcentral.com/cmaj

Footnotes

Competing interests: None declared.

This article has been peer reviewed.

References

  • 1.Lemp MA. Advances in understanding and managing dry eye disease. Am J Ophthalmol 2008;146: 350–6 [DOI] [PubMed] [Google Scholar]
  • 2.Buchholz P, Steeds CS, Stern LS, et al. Utility assessment to measure the impact of dry eye disease. Ocul Surf 2006;4:155–61 [DOI] [PubMed] [Google Scholar]
  • 3.American Academy of Ophthalmology Cornea/External Disease Panel. Dry eye syndrome. Limited revision. San Francisco (CA): American Academy of Ophthalmology; 2011 [Google Scholar]
  • 4.Noble J, Lloyd JC. The red eye. CMAJ 2011;183:81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop. Ocul Surf 2007;5:163–78 [DOI] [PubMed] [Google Scholar]

Articles from CMAJ : Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES